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Introduction
The term "ubiquitin-proteasome system" (UPS) is generally used to refer to a multienzymatic machinery that mediates the physiological turnover of short-lived proteins, as well as the removal of misfolded, and hence potentially toxic, polypeptides. [1] [2] [3] This process is generally initiated by polyubiquitination, a reversible post-translational modification whereby several copies of ubiquitin, a small (76 residues, 8.5 kDa) highly-conserved polypeptide present in all eukaryotic cells, are covalently conjugated to target proteins. 4 In general terms, ubiquitination relies on 3 distinct classes of enzymes: (1) ubiquitin-activating E1 enzymes, which catalyze an ATP-dependent reaction that generates a high-energy ubiquitin-adenylate intermediate; 5 (2) ubiquitin-conjugating E2 enzymes, to which activated ubiquitin is attached to form an E2-ubiquitin thioester intermediate; 6 and (3) E3 ligases, which transfer ubiquitin from E2 intermediates to specific lysine residues on target proteins. 7 The human genome appears to encode 1-2 E1, approximately 40 E2, and more than 500 putative E3 enzymes. 8 When ubiquitination involves previously attached ubiquitin molecules (which contain several lysine residues), target proteins are tagged with multimeric ubiquitin chains, often (but not always) acting as a recognition signal for proteolytic degradation by the 26S proteasome.
The 26S proteasome is a multicomponent enzymatic complex composed of 1 or 2 19S regulatory cap subunits and a central 20S catalytic core. 1, [10] [11] [12] [13] [14] The 19S subunit is a ring-shaped particle that recognizes polyubiquitinated proteins and promotes either their ATP-dependent unfolding 3, 15 or the dismantling of ubiquitin chains, a reaction catalyzed by proteasome-associated deubiquitinases (DUBs). [16] [17] [18] The 20S subunit is a cylindrical pore consisting of 4 (2 a and 2 b) stacked rings composed of 7 subunits, 3 of which-b1, b3, and b5-are endowed with caspase-, trypsin-, and chymotrypsin-like enzymatic activities respectively. The 20S catalytic core hence mediates the nonspecific cleavage of polyubiquitinated proteins that have been unfolded by the 19S regulatory caps into small peptides and amino acids. [19] [20] [21] [22] [23] A detailed description of the regulation of the UPS, the pathophysiological relevance of alternative ubiquitin linkages (e.g., monoubiquitination, linear polyubiquitination), and deubiquitination reactions goes beyond the scope of this Trial Watch and can be found in several recent reviews. 1, 2, 6, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Besides playing a critical role in protein quality control, the UPS also regulates the abundance, enzymatic activity, and intracellular localization of several proteins involved in cellular processes as diverse as gene expression, cell cycle progression, differentiation, cell death, macroautophagy (hereafter referred to as autophagy), endocytosis, metabolic adaptation, antigen presentation, and inflammatory signaling. 24, 32, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Thus, the UPS resembles autophagy in that it is essential not only for the maintenance of cellular homeostasis in physiological settings, but also for adaptive responses to exogenous alterations of the intra-or extracellular microenvironment. [52] [53] [54] [55] [56] [57] Underscoring the importance of the UPS for the preservation of normal cellular functions, defects in the 26S proteasome and defects in E1, E2, or E3 ligases have been associated with several human disorders, including metabolic, cardiac, autoimmune, neurodegenerative, and neoplastic processes. 27, [58] [59] [60] [61] [62] The survival and proliferation of transformed cells, however, critically rely on an intact UPS, [63] [64] [65] [66] [67] [68] [69] possibly reflecting the phenomenon known as "non-oncogene addiction." 70, 71 Indeed, the activation of oncogenic pathways and the adverse microenvironmental conditions frequently encountered by growing neoplasms render malignant cells "addicted" to gene products and molecular systems that are not tumorigenic per se, such as members of the heat-shock protein (HSP) family, the autophagic machinery, and the UPS. 63, 67, [70] [71] [72] [73] [74] Targeting non-oncogene addiction represents a novel therapeutic paradigm with potentially high selectivity for cancer cells, stemming from the fact that normal tissues generally do not face adverse conditions, and hence do not rely on the continued activation of adaptive stress responses. 63, 67, 70, 71, [75] [76] [77] Today, 2 inhibitors of the 26S proteasome are approved by the US Food and Drug Administration (FDA) for use in humans: bortezomib and carfilzomib (source: http://www.fda. gov/). Bortezomib was approved for the treatment of relapsed multiple myeloma (MM) as early as in 2003 [78] [79] [80] [81] [82] and its indications have now been extended to MM patients in general as well as to individuals with mantle cell lymphoma (MCL) who have received at least one prior therapy. 80, 83, 84 Carfilzomib is currently licensed for use in subjects with MM who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 d of completion of the last therapy. 80, [85] [86] [87] [88] Milestone discoveries that have provided more precise insights into the UPS and fostered its exploitation as a target for anticancer therapy include: (1) the original description of a non-lysosomal pathway responsible for the clearance of intracellular misfolded proteins; 89 (2) the molecular characterization of the UPS as an ATP-consuming machinery that catalyzes the covalent ligation of ubiquitin to intracellular proteins for rapid proteolysis, 90 -92 a discovery that earned the 2004 Nobel Prize for Chemistry to the Israeli biologist Aaron Ciechanover, the Israeli biochemist Avram Hershko, and the American biologist Irwin A. Rose; 93 (3) identification of the 26S proteasome as the multisubunit component of the UPS that recognizes and degrades polyubiquitinated proteins; [94] [95] [96] and (4) the clinical development of bortezomib. 78, 79, 81, [97] [98] [99] [100] As part of our monthly Trial Watch series, [101] [102] [103] [104] [105] [106] in this article we describe the impact of the UPS on oncogenesis and tumor progression, followed by a critical discussion of recent clinical trials investigating the use of proteasome inhibitors in cancer patients. Of note, the robust clinical activity of thalidomide, lenalidomide, and pomalidomide, which are collectively referred to as immunomodulatory drugs, also relies (at least in part) on inhibition of the UPS. 107, 108 The clinical development of these agents has been summarized in a recent Trial Watch, 109 ,110 and will not be discussed further here.
Alterations of the UPS in Cancer
Accumulating evidence links alterations in the UPS to oncogenesis and tumor progression. Several E2 ligases are expressed at abnormal levels in human neoplastic tissues, including (but presumably not limited to) ubiquitin-conjugating enzyme E2Q family member 2 (UBE2Q2); 111,112 UBE2T; 113 UBE2B (also known as HR6B); 114,115 and UBE2C, an enzyme that is involved in the regulation of the metaphase-anaphase transition (also known as UBCH10).
116-119 Of note, high expression levels of UBE2C have been associated with aneuploidy and chromosome instability, 120 Targeting the 26S proteasome as an anticancer intervention Throughout the past 3 decades the effect of chemical UPS inhibitors on the survival and proliferation of cancer cells has been the subject of an intense wave of investigation, resulting in an abundant scientific literature. Most of these studies originated from the hypothesis that neoplastic cells have an increased demand for protein degradation and therefore rely on proteasomal functions to a greater extent than their non-transformed counterparts. [63] [64] [65] [66] This is presumably a consequence of the malignant phenotype itself, which is associated with severe proteotoxic stress, 66,178-180 and the adverse microenvironmental conditions frequently encountered by cancer cells. 66, [178] [179] [180] [181] [182] [183] In this context, three categories of compounds that have been shown to block the proteolytic activity of the 26S proteasome at the level of the 20S subunit have been, or are being, developed in the clinic: (1) boronate-based agents, encompassing bortezomib, delanzomib, and ixazomib; (2) peptide epoxyketone-based agents, such as carfilzomib and oprozomib; and (3) non-peptide b-lactone-based chemicals, including marizomib.
80,184
The antineoplastic activity of proteasome inhibitors is multifactorial and exhibits at least some degree of context dependency. Thus, the blockade of proteasomal protein degradation may exert cytostatic [185] [186] [187] [188] [189] or cytotoxic 185, [190] [191] [192] effects upon inhibition of the NF-kB signaling pathway, [193] [194] [195] [196] overproduction of reactive oxygen species (ROS), 186, [197] [198] [199] and activation of the mitogenactivated protein kinase 8 (MAPK8, best known as JNK1) and p53 signaling. 200 Proteasome inhibitors have also been shown to provoke endoplasmic reticulum (ER) stress by abrogating ERassociated protein degradation, [201] [202] [203] [204] de facto favoring the accumulation of misfolded or polyubiquitinated (and potentially toxic) proteins and impairing mitochondrial functions. 202, 205 In line with this notion, bortezomib efficiently triggers an immunogenic variant of apoptosis that critically relies on the establishment of ER stress. [206] [207] [208] [209] At least in part, the ability of bortezomib to kill cancer cells while promoting the establishment of a tumor-specific immune response may explain its clinical success in MM patients.
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Bortezomib
As mentioned above, bortezomib (also known as PS341 or Velcade Ò ) is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome. [213] [214] [215] [216] This boronate-based agent has been reported to mediate robust antineoplastic effects against a variety of human cancer cell lines in vitro and in vivo. [217] [218] [219] [220] This said, the sensitivity of malignant cells to bortezomib varies considerably among cancer cells of distinct histologic origin or that exhibit different oncogenic alterations. 221, 222 However, a large amount of preclinical data that accumulated in the early 2000s indicates that bortezomib is particularly efficient against otherwise chemoresistant hematologic malignancies, including MM. 220, [223] [224] [225] [226] Completed clinical studies In the past decade, dozens of studies have investigated the therapeutic profile of bortezomib in individuals with relapsed refractory MM ( Table 1) . The safety and antineoplastic activity demonstrated by bortezomib in initial Phase I-II trials 78, 79, 97, [227] [228] [229] drove the primary approval of this drug by the US FDA for use in MM patients who failed to benefit from at least 2 lines of previous therapy. Indeed, MM patients receiving bortezomib exhibited a response rate of approximately 37% (»27% partial responses, »10% complete or near-to-complete responses) and a median overall survival of 16 mo. 79 Subsequent clinical trials demonstrated the superior anticancer activity of (1) bortezomib monotherapy compared to high-dose dexamethasone (an FDAapproved glucocorticosteroid that exerts cytotoxic effects against several hematologic malignancies) [230] [231] [232] [233] in subjects with relapsed or refractory MM; 98,234 and (2) bortezomib combined with prednisone (another glucocorticosteroid licensed for use in cancer patients) 81, 235 and melphalan (an alkylating agent currently employed for the treatment of MM, ovarian carcinoma, and melanoma) 236 compared to melphalan plus prednisone in patients with newly diagnosed MM who were ineligible for high-dose chemotherapy. [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] Bortezomib employed as a stand-alone therapeutic intervention has also been associated with a good clinical profile (toxicity, response rate, and duration of response) in subjects with relapsed or refractory MCL, 83, 84 and in patients with recurrent or refractory follicular lymphoma. 247, 248 These data underpinned the approval of bortezomib for use in MCL [284] [285] [286] (7) bevacizumab (a monoclonal antibody targeting the vascular endothelial growth factor [VEGF] that is currently approved for the treatment of several neoplasms); [287] [288] [289] (8) fotemustine (another alkylating agent currently approved for use in melanoma patients) 290 ,291 and dexamethasone; 292 (9) fludarabine (a nucleoside analog used for the treatment of CLL) 293, 294 plus melphalan, used as a conditioning regimen before allogeneic stem cell transplantation; 295 and (10) intermediate-dose melphalan and autologous stem cell transplantation, followed by lenalidomide-based consolidation.
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Of note, bortezomib-based chemotherapeutic cocktails exert anticancer effects not only in MM patients, but also in subjects bearing other hematologic neoplasms. These include: (1) MCL patients receiving bortezomib plus gemcitabine (an immunostimulatory nucleoside analog used for the treatment of distinct solid malignancies); [297] [298] [299] (2) individuals with high-risk MDS treated with bortezomib combined with low-dose cytarabine (a nucleoside analog used for the treatment of different types of leukemia); 300-302 (3) NHL patients receiving bortezomib in combination with the FDA-approved CD20-targeting monoclonal antibody 90 Y-ibritumomab tiuxetan [303] [304] [305] or with rituximab plus low-dose dexamethasone; 306 (4) subjects with relapsed or refractory follicular lymphoma treated with bortezomib plus bendamustine and rituximab; 307 (5) diffuse large B-cell lymphoma (DLBCL) and MCL patients receiving bortezomib in the context of a rituximab-cyclophosphamide-, doxorubicin-, vincristine-, and prednisone-based chemotherapeutic combination commonly known as R-CHOP; 308 (6) NHL and MCL patients treated with bortezomib plus etoposide (an FDA-approved inhibitor of topoisomerase II commonly used for the treatment of several neoplasms), 309, 310 cytarabine, melphalan, and autologous hematopoietic stem cell transplantation; 311 (7) subjects with refractory DLBCL or peripheral T-cell lymphoma (TCL) receiving bortezomib plus gemcitabine. 312 The results of some Phase I clinical trials (mainly investigating safety, tolerability, and dosing schedules) supported the development of bortezomib in combination with other therapeutic interventions for the treatment of some solid malignancies. [313] [314] [315] [316] [317] [318] [319] [320] [321] [322] Nonetheless, the findings of Phase II trials performed so far are quite disappointing. Although well tolerated, bortezomib monotherapy displays limited, if any, clinical activity against chemotherapy-na€ ıve, metastatic non-small cell lung carcinoma (NSCLC), 323 advanced gastric or gastroesophageal junction adenocarcinoma, 324 unresectable hepatocellular carcinoma (HCC), 325 and advanced tumors of the biliary tract. 326 Along similar lines, various bortezomib-based chemotherapeutic cocktails have been shown to mediate negligible antineoplastic effects in patients with head and neck tumors, 327,328 recurrent glioblastoma, 329 malignant pleural mesothelioma, 330 metastatic breast carcinoma, 331 advanced NSCLC, 332 HCC, 333 castration-resistant metastatic prostate cancer, [334] [335] [336] and ovarian carcinoma. 337 Together, these observations suggest that bortezomib, alone or combined with other chemotherapeutic interventions, mediates significant therapeutic benefits exclusively in patients affected by hematologic malignancies. Interestingly, the elevated sensitivity of MM to bortezomib has been ascribed to the fact that MM cells (de facto originating from plasma cells) produce high titers of abnormal immunoglobulins and hence critically rely on the activity of the so-called immunoproteasome, a bortezomib-sensitive variant of the 26S proteasome that is upregulated in response to inflammatory cytokines. [338] [339] [340] [341] In this setting, the relatively low efficiency of bortezomib at the molecular level (bortezomib is estimated to reduce the global proteolytic activity of the 26S proteasome by 20-30%) 342 may be sufficient to efficiently kill transformed cells.
Ongoing clinical trials
Official sources list 15 ongoing (not terminated, withdrawn, suspended, or completed) clinical trials launched after January 1 2012 that are aimed at assessing the safety and antineoplastic activity of bortezomib as an off-label therapeutic intervention, i.e., in patients affected by malignancies other than MM and MCL (http://www.clinicaltrials.gov/) ( Table 2 ). In particular, bortezomib is being tested in individuals with: (1) relapsed or refractory acute lymphoblastic leukemia (ALL), in combination with doxorubicin, dexamethasone, vincristine (a microtubular poison currently licensed for the treatment of several malignancies), [343] [344] [345] and pegylated asparaginase (a recombinant enzyme commonly employed for this oncologic indication) (NCT01769209); (2) acute myeloid leukemia (AML), in combination with arsenic trioxide (NCT01950611), sorafenib (a FDAapproved multikinase inhibitor) [346] [347] [348] and decitabine (a nucleoside analog employed for the treatment of AML and MDS) 301, 349 (NCT01861314), liposomal doxorubicin (NCT01736943), or sorafenib plus the HDAC inhibitor vorinostat 350 (NCT01534260); (3) DLBCL, either as a stand-alone maintenance therapy (NCT01902862), or as an induction therapy in combination with rituximab, dexamethasone, cytarabine, and cisplatin (a platinum derivative commonly employed against several solid neoplasms) [351] [352] [353] [354] prior to high-dose chemotherapy and autologous stem cell transplantation (NCT01805557), or combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (NCT01848132); (4) low-or intermediate-risk MDS, as a single agent (NCT01891968); (5) Waldenstr€ om's macroglobulinemia (WM), combined with cyclophosphamide, rituximab and dexamethasone (NCT01788020) or with cyclophosphamide, rituximab, and fludarabine (NCT01592981); and (6) various hematologic malignancies, in combination with the experimental inhibitor of aurora kinase A (AURKA) alisertib and rituximab (NCT01695941) or a multicomponent chemotherapeutic cocktail (NCT02112916). Moreover, the therapeutic potential of bortezomib is being investigated in subjects with relapsed or refractory neuroblastoma, who receive it in combination with the ornithine decarboxylase inhibitor eflornithine (which is currently approved as a topical intervention against facial hirsutism and as a systemic treatment for sleeping sickness) [355] [356] [357] [358] (NCT02139397), and in NSCLC patients bearing KRAS mutations or with a limited smoking history, who are treated with bortezomib plus acyclovir (a guanosine analog currently approved for the treatment of herpes simplex virus infection) [359] [360] [361] [362] (NCT01833143).
Carfilzomib
Several MM patients either do not respond or become refractory to bortezomib monotherapy. [363] [364] [365] A variety of molecular alterations have been proved to contribute to such innate or acquired resistance, including overexpression of wild-type or mutant proteasome components; [366] [367] [368] [369] [370] constitutive activation of NF-kB 371, 372 or insulin-like growth factor 1 receptor (IGF1R) 373, 374 signaling; a block in mitochondrial apoptosis; 375 upregulation of the chaperones involved in the ER unfolded protein response; 376 increased expression levels of multidrug transporters; [377] [378] [379] and the elicitation of nuclear factor, erythroid 2-like 2 (NFE2L2)-dependent responses to oxidative stress. 380 This has driven the development of carfilzomib (also known as PR-171), a second-generation, epoxyketone-based, irreversible inhibitor of the chymotrypsin-like activity of the 26S proteasome. [381] [382] [383] Carfilzomib rapidly turned out to mediate robust antineoplastic effects against several hematologic malignancies (including MM) in vitro and in vivo. [381] [382] [383] Similar to that of bortezomib, the pronounced antimyeloma activity of carfilzomib has been attributed to its ability to inhibit the immunoproteasome. 383 Table 3 ). In one of these studies, carfilzomib was associated with durable clinical responses (overall response rate 23.7%, median duration of response 7.8 mo, median overall survival 15.6 mo) and an acceptable toxicity profile, 87 supporting approval of this agent by the FDA for the treatment of relapsed and refractory MM patients who have received at least 2 prior therapies, including bortezomib. 386 Importantly, a prospective analysis performed on this patient cohort revealed that singleagent carfilzomib has the potential to at least partially overcome the impact of high-risk cytogenetics in heavily pretreated MM patients. 387 Moreover, carfilzomib appears to be associated with a reduced incidence of peripheral neuropathy (13.9%). 388 The combination of carfilzomib with lenalidomide and dexamethasone also seems to be well tolerated and to promote robust, rapid, and durable responses in patients with both relapsed/progressive 389, 390 and newly diagnosed 391 MM. In particular, 62% of individuals with newly diagnosed MM achieved at least a nearcomplete clinical response in response to this chemotherapeutic cocktail, with a 2-y progression-free survival estimate of 92%. 391 Recently, an open-label, intra-patient Phase I/II clinical trial demonstrated that replacing bortezomib with carfilzomib is safe and can provide therapeutic benefits to MM patients who are progressing on bortezomib-based combinatorial chemotherapy. 392 Moreover, the results of a Phase II study indicate that combining carfilzomib with cyclophosphamide and dexamethasone is associated with a good safety profile and high rates of complete response among patients with newly diagnosed MM. 393 A randomized, open-label Phase III study is currently ongoing to compare the overall survival of carfilzomib monotherapy to best supportive care in relapsed or refractory MM patients. 394 Of note, similar to bortezomib, carfilzomib is well tolerated by patients with advanced solid tumors but exerts limited, if any, antineoplastic activity. 395 Ongoing clinical trials Official sources list 14 ongoing (not terminated, withdrawn, suspended, or completed) clinical trials launched after January 1 2012 to investigate the therapeutic profile of carfilzomib as an off-label therapeutic intervention, i.e., in patients affected by neoplasms other than MM (http://www.clinicaltrials.gov/) ( Table 4) . Carfilzomib is being evaluated as a stand-alone therapeutic intervention in patients with (1) relapsed or refractory MCL (NCT02042950); (2) refractory renal cell carcinoma (NCT01775930); or (3) advanced malignancies (NCT01949545). Moreover, the safety and efficacy of carfilzomib are being tested in (1) patients with relapsed or refractory DLBCL, receiving carfilzomib in the context of rituximab-based chemotherapy (NCT01959698; NCT02073097); (2) subjects with relapsed or refractory MCL, who are treated with carfilzomib plus lenalidomide and rituximab (NCT01729104); (3) patients with relapsed or refractory NHL, receiving carfilzomib in combination with an FDAapproved histone deacetylase inhibitor (belinostat) 271, [396] [397] [398] (NCT02142530) or bendamustine and rituximab (NCT02187133); (4) patients with relapsed WM, with carfilzomib, rituximab, and dexamethasone (NCT01813227); (5) subjects with cutaneous TCL, receiving carfilzomib plus the FDA-approved HDAC inhibitor romidepsin [397] [398] [399] [400] (NCT01738594); and (6) MCL, TCL, and DLBCL patients, who are treated with carfilzomib and dexamethasone as consolidation therapy after autologous stem cell transplantation (NCT01926665). Finally, the clinical profile of carfilzomib is being assessed in (1) previously untreated subjects affected by extensive stage small-cell lung cancer, who are treated with carfilzomib plus carboplatin (a platinum derivative employed for the treatment of multiple solid tumors, including ovarian carcinoma) [401] [402] [403] and etoposide (NCT01987232); (2) subjects with relapsed lung cancer, receiving carfilzomib in combination with irinotecan (a topoisomerase I inhibitor mainly used for the treatment of colorectal carcinoma) 404, 405 (NCT01941316); 335 who are treated with carfilzomib, dexamethasone, and acyclovir (NCT02047253).
Completed clinical studies
Additional proteasome inhibitors
Other clinically relevant inhibitors of the 26S proteasome include: (1) marizomib (also known as NPI-0052), an irreversible inhibitor of both the chymotrypsin-and trypsin-like enzymatic activities of the 20S subunit [406] [407] [408] [409] [410] that exhibits improved bioavailability compared to bortezomib and carfilzomib, perhaps because of its non-peptidic nature, 411 and robust antineoplastic activity in preclinical models; 190, [412] [413] [414] [415] ixazomib (also known as MLN9708), a boronate-based agent characterized by increased oral availability and antitumor activity compared to bortezomib; 184, 416 (3) oprozomib (also known as ONX-0912), a carfilzomib-like orally bioavailable inhibitor of the chymotrypsin-like activity of the 20S subunit, 417, 418 which is active against MM and head and neck cancers; 419, 420 and (4) delanzomib (also known as CEP-18770), a potent, reversible, and orally bioavailable agent [421] [422] [423] [424] exhibiting high antineoplastic activity in preclinical models of MM both as monotherapy 425 and in combination with other chemotherapeutic agents. 425, 426 Intriguingly, some of these chemicals, including marizomib, have been reported to synergize with bortezomib in the killing of MM cells, 409, 427 suggesting that the mechanisms of action of distinct proteasome inhibitors may not be completely overlapping.
Clinical studies
Marizomib-based monotherapy has been associated with a promising safety profile (no evidence of thrombocytopenia and peripheral neuropathy) and clinical efficacy in Phase I trials enrolling relapsed and refractory MM patients. 80, 407, 411, 428 In addition, the combination of marizomib and vorinostat was well tolerated by patients with advanced solid tumors. 429 According to official sources (http://www.clinicaltrials.gov/, ongoing trials initiated after January 1 2012), the safety and antineoplastic activity of marizomib are currently being assessed in relapsed or refractory MM patients, receiving marizomib either as a standalone therapeutic intervention (NCT00461045) or in combination with pomalidomide (an immunomodulatory agent approved by the US FDA for the treatment of MM) 110,430-433 and lowdose dexamethasone (NCT02103335) ( Table 5) .
The safety and tolerability of ixazomib have been evaluated in several Phase I clinical trials enrolling subjects with relapsed/ refractory MM. [434] [435] [436] [437] [438] [439] [440] In 2 of these studies, 15-18% of patients were reported to achieve at least a partial response to therapy, 434, 435 supporting further clinical development. Along similar lines, ixazomib (co-administered with dexamethasone and lenalidomide) was well tolerated by individuals with previously untreated MM and exerted some degree of clinical activity. 441, 442 According to official sources, no fewer than 14 clinical trials have been initiated after January 1 2012 to evaluate the therapeutic potential of ixazomib in subjects with hematologic malignancies (http://www.clinicaltrials.gov/). In these studies, ixazomib is being tested (1) as a single agent for posttransplantation maintenance in patients with MM (NCT02168101; NCT02181413) or various hematologic tumors including MM (NCT02169791); (2) in combination with dexamethasone for relapsed and refractory (NCT01830816) or relapsed but not refractory (NCT01415882) MM; (3) in combination with dexamethasone and cyclophosphamide in newly-diagnosed MM patients (NCT01864018, NCT02046070); (4) in combination with dexamethasone and panobinostat (an experimental non-selective HDAC inhibitor) 397, 398 in subjects with relapsed and/or refractory MM (NCT02057640); (5) in combination with dexamethasone and pomalidomide in refractory (NCT02004275) or relapsed/refractory (NCT02119468) MM patients; (6) with lenalidomide only, as a maintenance regimen upon autologous stem cell transplantation in MM patients (NCT01718743); (7) with lenalidomide and dexamethasone, in patients with either newly diagnosed (NCT01850524, NCT01936532) or relapsed/ refractory (NCT01564537, NCT01645930) MM. Moreover, ixazomib monotherapy is being evaluated in non-MM patients, including (1) subjects with relapsed or refractory AML (NCT02030405); (2) individuals with relapsed/refractory cutaneous and peripheral TCL (NCT02158975); (3) patients with relapsed/refractory follicular lymphoma (NCT01939899); (4) subjects with hematologic malignancies or advanced solid tumors (NCT01912222); and (5) individuals with lymphomas or advanced solid tumors (NCT01953783). Finally, ixazomib is being assessed in combination with (1) mitoxantrone (an FDAapproved immunogenic anthracycline used for the therapy of NHL, AML, and breast carcinoma), [443] [444] [445] [446] etoposide, and intermediate-dose cytarabine in relapsed/refractory AML patients (NCT02070458); (2) vincristine, doxorubicin, pegylated-asparaginase, and dexamethasone in subjects with relapsed/refractory ALL or lymphoma (NCT01887587); and (3) vorinostat, in individuals with advanced solid tumors (NCT02042989) ( Table 5) .
The safety and tolerability of oprozomib have been evaluated in Phase I studies performed on patients with hematologic malignancies and advanced solid tumors. 447, 448 According to official sources (http://www.clinicaltrials.gov/, ongoing trials initiated after January 1 2012), the clinical profile of oprozomib is being investigated in (1) transplantineligible patients with newly diagnosed MM, receiving oprozomib plus dexamethasone and lenalidomide (NCT01881789), or dexamethasone and oral cyclophosphamide (NCT01881789), or prednisone and melphalan (NCT02072863), (2) relapsed and/or refractory MM patients, treated with oprozomib plus dexamethasone (NCT01832727); and (3) subjects with primary refractory or relapsed/refractory MM, receiving oprozomib with pomalidomide and dexamethasone (NCT01999335) ( Table 5) .
Finally, results from a relatively recent Phase I clinical trial enrolling patients with advanced solid tumors and MM demonstrated a favorable safety profile for delanzomib, which in this setting was not associated with significant neurotoxicity and skin toxicity. 449 The clinical development of this proteasome inhibitor has nonetheless been discontinued due to a lack of efficacy documented in a Phase I/II trial conducted on relapsed refractory MM patients.
411,450
Concluding Remarks
The clinical advantages provided by proteasome inhibitors to MM patients have been demonstrated by a large number of clinical studies. However, bortezomib, carfilzomib, and similar agents generally lack therapeutic activity against solid tumors. In addition, the clinical activity of proteasome inhibitors in MM patients can be limited by (1) 461 , the implementation of novel combinatorial chemotherapeutic regimens, and the development of third-generation proteasome inhibitors with improved bioavailability and reduced toxicity may broaden the therapeutic utility of these compounds against hematologic malignancies and solid tumors. As an alternative, therapeutic strategies targeting other components of the UPS and DUBs have been proposed. Although such an approach holds promise, only a few compounds such as MDM2 antagonists (e.g., nutlin-3, serdemetan) and NEDD8-activating enzyme (NAE) inhibitors (e.g., MLN4924) have entered clinical development to date. 462, 463 Accumulating evidence indicates that regulation of the UPS in both physiologic and pathologic settings is more complex than originally thought, which complicates the development of clinically useful proteasome targeting agents 64, 464 Moreover, limiting proteasomal protein degradation in healthy tissues may favor tumorigenesis (by stabilizing oncoproteins or inhibiting tumor suppressors) and/or neurodegenerative disorders (by promoting the accumulation of potentially neurotoxic misfolded proteins).
64, 464 Along similar lines, the UPS plays a critical role in the processing of intracellular proteins for antigen presentation, 32, 50, [465] [466] [467] [468] implying that proteasome inhibitors may negatively affect the elicitation of therapeutically relevant anticancer immune responses.
An improved understanding of the composition, function, and regulation of the UPS, as well as the molecular mechanisms underlying the intrinsic or acquired resistance of some neoplasms to proteasome-targeting agents, may pave the way to the design of novel effective anticancer chemotherapies based on proteasome inhibition and to their successful translation from the bench to the bedside.
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